Physician profile
Param Dedhia
NPI 1396780136
$636,142.83
in general payments reported to CMS, 2019-2025
17 companies · $473K in 2025
The $473K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $256 · 2023: $118K · 2024: $45K · 2025: $473K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $592K · Travel and Lodging: $42K · Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $592,200.00 |
| Travel and Lodging | $41,890.67 |
| Food and Beverage | $1,681.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $635,619.44 | 2023-2025 | |
| Abbvie INC. | $94.49 | 2021-2022 | |
| Amgen INC. | $87.08 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $44.82 | 2021-2022 | |
| Csl Behring | $43.47 | 2022 | |
| Lilly USA, LLC | $31.93 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.71 | 2023 | |
| Nestle Healthcare Nutrition INC. | $31.21 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.82 | 2022-2023 | Jardiance |
| Glaxosmithkline, LLC. | $22.40 | 2023 | Trelegy Ellipta |
| Kyowa Kirin, INC. | $20.16 | 2022 | |
| Itamar Medical INC | $18.20 | 2023 | Watchpatone |
| Astrazeneca Pharmaceuticals Lp | $17.16 | 2023 | Farxiga |
| Aimmune Therapeutics, INC. | $14.53 | 2024 | |
| Astellas Pharma US INC | $13.88 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $11.38 | 2021 | |
| Ucb, INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Param Dedhia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.